Skip to main content
. 2021 Jun 1;11:11427. doi: 10.1038/s41598-021-91012-w

Figure 1.

Figure 1

Significance testing of ovarian signature scores stratified by clinical response. ssGSEA was applied with gene signature sets tailored to ovarian cancer, resulting in per-signature scores normalized to the range 0–1. The clear cell signature is significant in complete responders and the proliferative signature was significantly different in patients who exhibited progressive disease. The PR* group comprises one patient classified as PR by RECIST protocols and one exceptional patient (see “Methods”). Image was created using Prism version 8.3.0 (https://www.graphpad.com/).